AIM: To evaluate the safety and efficacy by short-term following up of choroidal neovascularization(CNV)in high myopia treated with intravitreal Conbercept.

METHODS: Totally 19 eyes from 19 high myopia patients with CNV were reviewed after intravitreal Conbercept therapy. They were all diagnosed in the Ophthalmology Department of our hospital between April 2016 and February 2018. They were between 35 to 73 years old and the average age was 55.40±11.75 years old, 8 male and 11 female. The spherical equivalent refractive error of the 19 eyes was ranged from -19.00D to -7.50D whose mean value was -12.70D±3.23D. All these patients received intravitreal conbercept 0.5mg/0.05mL once per month for 3mo. The clinical features like age, gender, systemic disease, best corrected visual acuity(BCVA)and intraocular pressure(IOP), exudation of CNV by fundus fluorescein angiography(FFA)and central macular thickness(CMT)by optical coherence tomography(OCT)were evaluated before the treatment. The BCVA and IOP were observed after 1d, 1wk, 1mo of each treatment, and the CMT was recorded by OCT after 1wk, 1mo of each treatment, also the variety of CNV that present in FFA was observed after 1mo of the last treatment. These data was compared to the basal data that before intravitreal injection of conbercept to evaluate the clinical efficacy, and the adverse drug reaction was noticed as well. SPSS was used to analysis the change of parameters after treatment for CNV secondary to high myopia.

RESULTS: The pre-injection mean BCVA(LogMAR)at baseline was 0.98±0.29. At the last follow-up visit, the mean post-injection LogMAR BCVA was 0.64±0.16. CMT improved from 324.9±55.6μm to 248.7±17.7μm. The mean post-injection LogMAR BCVA and CMT after each time treatment were both improved than before treatment(P<0.05). However, the data observed after injection was not improved between each other(P>0.05). In these 19 patients, elevated IOP did not occur, besides individual patients had conjunctival hemorrhage, no other significant ocular or systemic injection complications or drug-related side effects were observed.

CONCLUSION: The outcomes of this small case series suggest intravitreal Conbercept to be a safe and promising treatment method for CNV secondary to high myopia with both visual and anatomic improvements and the effect is obvious at the first time injection.